Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FHD-286 + Decitabine/Venetoclax in AML
NCT07283094Phase 1Recruiting
- Sponsor
- Montefiore Medical Center
- Start
- Feb 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camibirstat in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Montefiore Medical Center. Primary endpoints: Dose-limiting toxicities at 12 weeks, Adverse event of special interest at 12 weeks and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
camibirstat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07283094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283094.